His primary areas of investigation include Internal medicine, Gastroenterology, Fatty liver, Nonalcoholic fatty liver disease and Liver biopsy. He combines topics linked to Endocrinology with his work on Internal medicine. Rohit Loomba has included themes like Prospective cohort study, Surgery, Diabetes mellitus, Insulin resistance and Placebo in his Gastroenterology study.
Rohit Loomba works mostly in the field of Placebo, limiting it down to topics relating to Randomized controlled trial and, in certain cases, Placebo-controlled study, as a part of the same area of interest. His Fatty liver research integrates issues from Chronic liver disease, Liver disease, Metabolic syndrome and Liver cancer. His Nonalcoholic fatty liver disease study integrates concerns from other disciplines, such as Biomarker, Steatosis, Transient elastography and Receiver operating characteristic.
His primary scientific interests are in Internal medicine, Gastroenterology, Nonalcoholic fatty liver disease, Fatty liver and Fibrosis. The study of Internal medicine is intertwined with the study of Cardiology in a number of ways. His research investigates the link between Gastroenterology and topics such as Placebo that cross with problems in Randomized controlled trial.
His study in Nonalcoholic fatty liver disease is interdisciplinary in nature, drawing from both Body mass index, Liver disease, Magnetic resonance imaging and Chronic liver disease. The concepts of his Fatty liver study are interwoven with issues in Biomarker, Endocrinology and Metabolic syndrome. His biological study spans a wide range of topics, including Nonalcoholic steatohepatitis and Magnetic resonance elastography.
Rohit Loomba mainly investigates Internal medicine, Gastroenterology, Nonalcoholic fatty liver disease, Fibrosis and Fatty liver. Many of his studies involve connections with topics such as Cardiology and Internal medicine. Rohit Loomba has researched Gastroenterology in several fields, including Diabetes mellitus, Placebo and Cohort.
His research integrates issues of Magnetic resonance imaging, Type 2 diabetes, Metabolic syndrome and Clinical trial in his study of Nonalcoholic fatty liver disease. The Fatty liver study combines topics in areas such as Magnetic resonance elastography and Elastography. His Cirrhosis study incorporates themes from Microbiome and Hepatocellular carcinoma.
Rohit Loomba mainly focuses on Internal medicine, Gastroenterology, Nonalcoholic fatty liver disease, Fibrosis and Cirrhosis. His study in Hepatocellular carcinoma, Steatohepatitis, Liver biopsy, Confidence interval and Odds ratio is carried out as part of his Internal medicine studies. His Gastroenterology research incorporates themes from Proton density fat fraction, Placebo and Fatty liver.
His research in Nonalcoholic fatty liver disease intersects with topics in Biomarker, Prospective cohort study, Metabolic syndrome and Type 2 diabetes. As a part of the same scientific study, Rohit Loomba usually deals with the Fibrosis, concentrating on Agonist and frequently concerns with Urology, Regression, Resolution and Adiponectin. The study incorporates disciplines such as Microbiome, Genetics and Decompensation in addition to Cirrhosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis
Rohan Khera;Mohammad Hassan Murad;Apoorva K. Chandar;Parambir S. Dulai.
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A Neuschwander-Tetri;Rohit Loomba;Arun J Sanyal;Joel E Lavine.
The Lancet (2015)
The global NAFLD epidemic
Rohit Loomba;Arun J. Sanyal.
Nature Reviews Gastroenterology & Hepatology (2013)
Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
Siddharth Singh;Alina M. Allen;Zhen Wang;Larry J. Prokop.
Clinical Gastroenterology and Hepatology (2015)
Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19.
Peng Zhang;Lihua Zhu;Jingjing Cai;Fang Lei.
Circulation Research (2020)
Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.
Parambir S. Dulai;Siddharth Singh;Janki Patel;Meera Soni.
Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease
Chris Estes;Homie Razavi;Rohit Loomba;Zobair Younossi.
Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy.
Rohit Loomba;Ayana Rowley;Robert Wesley;T. Jake Liang.
Annals of Internal Medicine (2008)
Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
Chris Estes;Quentin M. Anstee;Maria Teresa Arias-Loste;Heike Bantel.
Journal of Hepatology (2018)
A Randomized, Placebo-Controlled Trial of Cenicriviroc for Treatment of Nonalcoholic Steatohepatitis with Fibrosis
Scott L. Friedman;Vlad Ratziu;Stephen A. Harrison;Manal F. Abdelmalek.
Journal of Hepatology
(Impact Factor: 30.083)
Alimentary Pharmacology and Therapeutics
(Impact Factor: 9.524)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: